H3-DYNAMICS
15.12.2022 14:34:41 CET | Business Wire | Press release
H3 Dynamics and HyLight have joined forces to bring new long range, sustainable and quiet unmanned airships to a range of commercial applications. Traditionally, airships use combustion engines for their propulsion power. With new hydrogen propulsion system developments at H3 Dynamics, HyLight’s new breed of airships will now offer long-range zero emission flight and open a whole new category in air mobility. The two companies share a common goal, to decarbonize the aerial industry.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221215005555/en/
HyLight’s compact airship is powered by H3 Dynamics hydrogen air-mobility power systems
HyLight and H3 Dynamics started working together several months ago in France, and HyLight have now achieved a first successful hydrogen-electric flight test campaign in Milan, Italy. HyLight is an up and coming french start-up and one of the very few companies in the world that was able to demonstrate hydrogen as a viable power supply for small unmanned airships in real conditions. This was made possible with H3 Dynamics’ aerospace-grade hydrogen fuel cells - the smallest and lightest in the world - have pioneered hydrogen flight research from as early 2006.
HyLight’s unmanned airships move slowly but don’t need to consume any power to stay aloft. They can operate for days at a time with heavier payloads compared to conventional drones, to conduct long range inspection of critical energy assets like power-lines & pipelines or scan industrial infrastructure over long distances. Airships could also hover around specific areas to provide critical connectivity for large scale industrial sites - or provide vital communications after a natural disaster.
Based in Toulouse, H3 Dynamics is set on decarbonizing air mobility with clean hydrogen-electric propulsion, starting with enabling smaller unmanned systems - whether fixed wing, multi-rotor or VTOL platforms. Its ultra-light power technology is bringing new long electric flight durations to the global unmanned aviation market, which is set to reach $38 Billion by 2027.
Earlier this year H3 Dynamics flew the world’s first distributed hydrogen-electric nacelles on a small unmanned platform, proving the potential for larger size systems in bigger aircraft. H3 Dynamics has since become part of the “Toulouse Pioneers” group linked to the Aerospace History Museum “L’Envol des Pionniers”. The company plans to scale its solutions to larger unmanned and manned aviation platforms over the coming years.
HyLight will leverage H3 Dynamics’ international presence covering Europe, North and South America as well as Asia and Australia to bring “made in France” hydrogen-electric airships to the global market.
About HyLight: https://www.hylight.aero
HyLight wants to decarbonize the aerial data industry by providing long-range aerial data collection and analysis services using its unmanned airship systems for the inspection of power lines, pipelines, and railways. Its airship come with hydrogen electric propulsion making them sustainable, silent, efficient, and long-range to cover large areas or distances. The company was started in France and has recently demonstrated the first flight of its hydrogen-electric platform. HyLight was selected to participate in the 1st Batch of the acceleration program of Berkeley SkyDeck Europe, Milano ; the company is also a member of the Hub Drone Systematic and U-LTA and has been financially supported by La Région Grand Est in France.
About H3 Dynamics www.h3dynamics.com
H3 Dynamics is based in Toulouse, Austin and Singapore - and is on a mission to decarbonize aviation with a unique technology solution around distributed hydrogen-electric propulsion, as well as ground refueling solutions. The company’s initial commercial focus is on the scale up of autonomous digital services that link to networks of charging stations for off-the-shelf battery-drones, making way for BVLOS hydrogen UAS capability. H3 Dynamics is a member of the Alliance for Zero Emission Aviation under the European Commission, Sustainable Aero Lab, the Lufthansa Cleantech Hub, the Paris Advanced Air Mobility Alliance, and Aerospace Valley in Toulouse.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221215005555/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom